Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method

Haemophilia

Volumn 19, Issue 6, 2013, Pages 920-925

  Cabrera, N ^a   Moret, A ^a   Caunedo, P ^a   Cid, A R ^a   Vila, V ^a   Espana F ^a   Aznar, J A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Chemiluminescence; Ristocetin cofactor activity; Von Willebrand disease; Von Willebrand factor activity.

Indexed keywords

RISTOCETIN; VON WILLEBRAND FACTOR;

ARTICLE; AUTOMATION; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THROMBOCYTE AGGLUTINATION;

CHEMILUMINESCENCE; RISTOCETIN COFACTOR ACTIVITY; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR ACTIVITY.;

AUTOMATION; HUMANS; IMMUNOASSAY; LUMINESCENT MEASUREMENTS; PHENOTYPE; RISTOCETIN; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84886641628     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12203     Document Type: Article

References (14)

1. Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011; 37: 440-55.
2. Nichols WL, Rick ME, Ortel TL et al. Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol 2009; 84: 366-70.
3. Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease; a report of the subcommitte on von Willebrand factor. J Thromb Haemost 2006; 4: 2103-14.
4. Budde U, Drewke E, Mainusch K, Schneppenheim R. Laboratory diagnosis of congenital von Willebrand disease. Semin Thromb Hemost 2002; 28: 173-89.
5. Favaloro EJ, Lillicrap D, Lazzari MA et al. Von Willebrand disease: laboratory aspects of diagnosis and treatment. Haemophilia 2004; 10: 164-8.
6. Jennings I, Kirchen DP, Woods TA, Kirchen S, Walker ID, Preston FE. Laboratory performance in the World Federation of Hemophilia EQA programme, 2003-2008. Haemophilia 2009; 15: 571-7.
7. Favaloro EJ, Smith J, Petinos P, Hertzberg H, Koutts J. Laboratory testing for von willerand disease: an assessment of current diagnostic practice and efficacy by means of a multilaboratory survey. Thromb Haemost 1999; 82: 1276-82.
8. Flood VH, Friedman KD, Gill JG et al. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost 2009; 7: 1832-9.
9. Vanhoorelbeke K, Pareyn I, Schlammadinger A et al. Plasma glycocalicin as a source of GPIbα in the von Willebrand factor ristocetin cofactor ELISA. Thromb Haemost 2005; 93: 165-71.
10. Federici AB, Canciani MT, Forza I et al. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibα for the diagnosis of patients with low von Willebrand factor levels. Haematologica 2004; 89: 77-85.
11. Howard MA, Firkin BG. Ristocetin-a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 362-9.
12. Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 2006; 32: 485-91.
13. Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol 2001; 14: 337-47.
14. Favaloro EJ, Bonar R, Marsden K. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008; 21: 178-83.